Ablative therapy for movement disorders: Thalamotomy for Parkinson's disease

Thalamotomy for Parkinson's disease is a well-established procedure that has been in use for more than 40 years. Technologic advances, such as computerized and magnetic resonance imaging, and refinement of stereotactic techniques have increased the safety and efficacy of this procedure. Current studies reveal good results in 70% to 90% of patients. Reported transient neurologic deficits occur in up to 60% of patients undergoing this procedure, although the highest permanent complication rates have decreased to around 10% to 20%. These data suggest the safety and efficacy of thalamotomy as a primary therapeutic option for selected patients with parkinsonian tremor.